Filtered By:
Specialty: Biotechnology
Source: Current Pharmaceutical Biotechnology
This page shows you your search results in order of date.
Order by Relevance | Date
Total 30 results found since Jan 2013.
The combination of baicalin with knockdown of miR148a gene suppresses cell viability and proliferation and induces the apoptosis and autophagy of human glioblastoma multiforme T98G and U87MG cells
CONCLUSION: The siRNA-induced miR148a mRNA knockdown in combination with baicalin may offer a novel therapeutic strategy to more effective control the growth of human GBM cells. Thus, knockdown of this gene in combination with baicalin inhibits proliferation (cell cycle arrest in S phase in T98G but not in U87MG cells), induces apoptosis and regulates autophagy in T98G and U87MG cells, but further studies urgently needed to confirm a positive phenomenon for the treatment of GBM.PMID:35761505 | DOI:10.2174/1389201023666220627144100
Source: Current Pharmaceutical Biotechnology - June 28, 2022 Category: Biotechnology Authors: Monika Paul-Samojedny Emilia Liduk Ma łgorzata Kowalczyk Paulina Borkowska Aleksandra Zieli ńska Renata Suchanek-Raif Jan Kowalski Source Type: research
Current synopsis on siRNA therapeutics as a novel anti-cancer and antiviral strategy: Progress and challenges
This article stated the development in the RNA polymer and also provides some examples of their diagnostic applications and therapeutics special emphasis on the anti-cancer and antiviral strategy. Patisiran and Givosiran are the recently approved si-RNA based products available in the market.PMID:35578839 | DOI:10.2174/1389201023666220516120432
Source: Current Pharmaceutical Biotechnology - May 17, 2022 Category: Biotechnology Authors: Sanjay Sharma Rupesh K Gautam Abhishek Kanugo Dinesh Kumar Mishra Mohammad Amjad Kamal Source Type: research
